Dr. Eric P. Shakin, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,461
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
NY license 159286
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore University Hospital Manhasset, NY
Medical groups
- Long Island Vitreo Retinal Consultants PC (20 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,461
- Services billed
- 30,791
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 11,640 | 49 |
| Imaging of retina | 2,948 | 1,257 |
| Injection, aflibercept, 1 mg | 2,434 | 353 |
| Injection of drug into eye | 1,787 | 514 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 1,521 | 115 |
| Established patient problem focused exam of visual system | 867 | 509 |
| Extended exam of the back part of the eye with retinal drawing | 837 | 653 |
| Injection, ranibizumab, 0.1 mg | 765 | 84 |
| Established patient office or other outpatient visit, 20-29 minutes | 699 | 554 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 480 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Great Neck, NY | 104 |
| Ketorolac Tromethamine Other prescribers in Great Neck, NY | 73 |
| Bromfenac Sodium | 54 |
| Ofloxacin Other prescribers in Great Neck, NY | 48 |
| Latanoprost Other prescribers in Great Neck, NY | 38 |
| Dorzolamide Hcl Other prescribers in Great Neck, NY | 30 |
| Brimonidine Tartrate Other prescribers in Great Neck, NY | 28 |
| Erythromycin (erythromycin base) Other prescribers in Great Neck, NY | 27 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Great Neck, NY | 24 |
| Ilevro (nepafenac) | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 26 payments worth $571 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $315 |
|---|---|
| Genentech USA, Inc. | $175 |
| AbbVie Inc. | $54.68 |
| Astellas Pharma US Inc | $26.40 |
| Food and Beverage | $571 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.